Literature DB >> 29616329

Proliferative glomerulonephritis with monoclonal IgG deposits in children and young adults.

Guolan Xing1, Robert Gillespie2, Badreldin Bedri2, Albert Quan3, Pingchuan Zhang4,5, Xin J Zhou6,7.   

Abstract

BACKGROUND: Proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) has been recognized as a distinct entity in recent years. To the best of our knowledge, all patients with PGNMID reported thus far were older than 20 years of age. We now report five cases of PGNMID in patients under 20 years of age.
METHODS: The clinical database was searched for patients with native kidney biopsies from 9/2011 to 8/2017, and cases with a diagnosis of PGNMID were retrieved. Light microscopy specimens and immunofluorescence and electron microscopy images were revisited. Clinical data and kidney biopsy findings for patients under the age of 20 were recorded.
RESULTS: Five (0.78%) of a total of 637 patients younger than 20 with native renal biopsies had a diagnosis of PGNMID, including three males and two females with an average age of 14 years old (range 10-19). All five patients presented with microscopic hematuria and proteinuria. Three patients were nephrotic and their C3 levels were low. All five cases showed a membranoproliferative pattern with abundant mesangial and subendothelial monoclonal IgG3 deposits (3 κ and 2 λ light chain, respectively). The patients were followed up to 56 months. Two patients had re-biopsies 28 and 18 months after initial diagnosis and both showed similar morphologic changes. Various treatments were attempted including prednisone, mycophenolate mofetil, tacrolimus, rituximab, and eculizmab, with mixed responses.
CONCLUSIONS: PGNMID does occur in children and young adults. Membranoproliferative glomerulonephritis pattern with monoclonal IgG3 deposits is a common feature. Despite various immunosuppressive treatments, the disease appears slowly progressive.

Entities:  

Keywords:  Children; Glomerulonephritis; Histopathology; Kidney biopsy; Membranoproliferative glomerulonephritis

Mesh:

Substances:

Year:  2018        PMID: 29616329     DOI: 10.1007/s00467-018-3949-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  22 in total

1.  Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases.

Authors:  Sean J Barbour; Monica C Beaulieu; Nadia Y Zalunardo; Alex B Magil
Journal:  Nephrol Dial Transplant       Date:  2011-06-01       Impact factor: 5.992

2.  Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits.

Authors:  Gauri Bhutani; Samih H Nasr; Samar M Said; Sanjeev Sethi; Fernando C Fervenza; William G Morice; Paul J Kurtin; Francis K Buadi; David Dingli; Angela Dispenzieri; Morie A Gertz; Martha Q Lacy; Prashant Kapoor; Shaji Kumar; Robert A Kyle; S Vincent Rajkumar; Nelson Leung
Journal:  Mayo Clin Proc       Date:  2015-05       Impact factor: 7.616

3.  The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits.

Authors:  Marguerite Vignon; Camille Cohen; Stanislas Faguer; Laure-Hélène Noel; Celine Guilbeau; Marion Rabant; Sarah Higgins; Aurélie Hummel; Alexandre Hertig; Hélène Francois; Moglie Lequintrec; Eve Vilaine; Bertrand Knebelmann; Jacques Pourrat; Dominique Chauveau; Jean-Michel Goujon; Vincent Javaugue; Guy Touchard; Khalil El Karoui; Frank Bridoux
Journal:  Kidney Int       Date:  2017-01-06       Impact factor: 10.612

4.  Monoclonal immunoglobulin-associated proliferative glomerulonephritis characterized by organized deposits of striated ultra-substructures: A case report.

Authors:  Shigeo Hara; Hiroyasu Tsukaguchi; Tastufumi Oka; Makiko Kusabe; Masayuki Mizui; Kensuke Joh
Journal:  Ultrastruct Pathol       Date:  2017-06-19       Impact factor: 1.094

5.  A case report of proliferative glomerulonephritis with monoclonal immunoglobulin M-kappa deposits without associated lymphoproliferative disorder or detectable paraproteinemia.

Authors:  Yoshito Yamaguchi; Kunihiko Maeda; Katsuyuki Nagatoya; Atsushi Yamauchi
Journal:  CEN Case Rep       Date:  2017-12-11

6.  Aggregation of gamma-G3 proteins: relevance to the hyperviscosity syndrome.

Authors:  J D Capra; H G Kunkel
Journal:  J Clin Invest       Date:  1970-03       Impact factor: 14.808

7.  Proliferative glomerulonephritis with monoclonal IgG deposits in a patient with autoimmune hemolytic anemia.

Authors:  Takashi Fujiwara; Atsushi Komatsuda; Hiroshi Ohtani; Masaru Togashi; Ken-Ichi Sawada; Hideki Wakui
Journal:  Clin Nephrol       Date:  2013-06       Impact factor: 0.975

8.  Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features.

Authors:  Jordan L Rosenstock; Glen S Markowitz; Anthony M Valeri; Giuseppe Sacchi; Gerald B Appel; Vivette D D'Agati
Journal:  Kidney Int       Date:  2003-04       Impact factor: 10.612

9.  Steroid-responsive nephrotic syndrome in a patient with proliferative glomerulonephritis with monoclonal IgG deposits with pure mesangial proliferative features.

Authors:  Atsushi Komatsuda; Hideki Wakui; Hiroshi Ohtani; Takashi Nimura; Ken-Ichi Sawada
Journal:  NDT Plus       Date:  2010-05-02

Review 10.  IgG subclasses and allotypes: from structure to effector functions.

Authors:  Gestur Vidarsson; Gillian Dekkers; Theo Rispens
Journal:  Front Immunol       Date:  2014-10-20       Impact factor: 7.561

View more
  2 in total

Review 1.  An update of proliferative glomerulonephritis with monoclonal immunoglobulin deposits.

Authors:  Manna Li; Gaosi Xu
Journal:  Clin Kidney J       Date:  2021-12-14

2.  Progression of proliferative glomerulonephritis with monoclonal IgG deposits in pediatric patients.

Authors:  Paul Miller; Andrew Y Xiao; Vanderlene L Kung; Richard K Sibley; John P Higgins; Neeraja Kambham; Vivek Charu; Colin Lenihan; Amanda M Uber; Elizabeth M Talley; Neiha Arora; Vighnesh Walavalkar; Zoltan G Laszik; Cynthia C Nast; Megan L Troxell
Journal:  Pediatr Nephrol       Date:  2020-10-12       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.